Platelet Dynamics in Peritoneal Carcinomatosis Patients Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Oxaliplatin

Journal Title: The AAPS Journal - Year 2016, Vol 18, Issue 1

Abstract

The aim of the study was to characterize the platelet count (PLT) dynamics in peritoneal carcinomatosis patients treated with cytoreductive surgery (CRS) and hyperthermic intraperitoneal oxaliplatin (HIO). Data from patients treated with CRS alone (N = 18) or CRS and HIO (N = 62) were used to estimate the baseline platelet count (PLT0), rate constants for platelet maturation (ktr) and platelet random destruction (ks), feedback on progenitor cell proliferation (γ), and the drug-specific model parameters (α, β). Plasma oxaliplatin concentrations, Cp, reduced the proliferation rate of progenitor cells (kprol) according to a power function α × Cpβ. The surgery effect on kprol and ks was explored. The typical values (between subject variability) of the PLT0, ktr, ks, γ, α, and β were estimated to be 237 × 109 cells/L (32.9%), 7.09 × 10−3 h−1 (47.1%), 8.86 × 10−3 h−1 (80.0%), 0.621, 0.88 L/mg (56.9%), and 2.63. Surgery induced a maximal 2.09-fold increase in kprol that was attenuated with a half-life of 8.42 days. Splenectomy decreased ks by 47.5%. Age, sex, body surface area, sex, total proteins, and HIO carrier solution did not impact the model parameters. The model developed suggests that, following CRS and HIO, thrombocytopenia and thrombocytosis were reversible and short-lasting; the severity of the thrombocytopenia and thrombocytosis was inversely correlated, with splenectomized patients having thrombocytopenia of lower severity and thrombocytosis of higher severity; and the HIO dose and treatment duration determine the severity and duration of the thrombocytopenia. Higher HIO dose or longer treatment duration could be used without substantially increasing the risk of major hematological toxicity.

Authors and Affiliations

Carlos Pérez-Ruixo, Belén Valenzuela, José Esteban Peris, Pedro Bretcha-Boix, Vanesa Escudero-Ortiz, José Farré-Alegre, Juan José Pérez-Ruixo

Keywords

Related Articles

Comparison of the rates of deamidation, diketopiperazine formation, and oxidation in recombinant human vascular endothelial growth factor and model peptides

In this work, we examine the way in which stability information obtained from studies on small model peptides correlates with similar information acquired from a protein. The rates of deamidation, oxidation, and diketopi...

Targeting opioid receptor heterodimers: Strategies for screening and drug development

G-protein-coupled receptors are a major target for the development of new marketable drugs. A growing number of studies have shown that these receptors could bind to their ligands, signal, and be internalized as dimers....

Current methodology to assess bioequivalence of levothyroxine sodium products is inadequate

Levothyroxine sodium is a drug with a narrow therapeutic index for which an individual patient must have his or her dose carefully titrated to achieve the necessary therapeutic effect. In addition, exogenous levothyroxin...

Stratification of Antibody-Positive Subjects by Antibody Level Reveals an Impact of Immunogenicity on Pharmacokinetics

The availability of highly sensitive immunoassays enables the detection of antidrug antibody (ADA) responses of various concentrations and affinities. The analysis of the impact of antibody status on drug pharmacokinetic...

Screening for Potential Adjuvants Administered by the Pulmonary Route for Tuberculosis Vaccines

Tuberculosis (TB) infects one third of the world’s population, and new infections occur at a rate of 1/s. Better vaccines are needed than the live mycobacterium Bacille Calmette-Guérin (BCG). Alveolar mac...

Download PDF file
  • EP ID EP680833
  • DOI  10.1208/s12248-015-9839-0
  • Views 56
  • Downloads 0

How To Cite

Carlos Pérez-Ruixo, Belén Valenzuela, José Esteban Peris, Pedro Bretcha-Boix, Vanesa Escudero-Ortiz, José Farré-Alegre, Juan José Pérez-Ruixo (2016). Platelet Dynamics in Peritoneal Carcinomatosis Patients Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Oxaliplatin. The AAPS Journal, 18(1), -. https://europub.co.uk/articles/-A-680833